The emerging era of pharmacogenomics: current successes, future potential, and challenges

作者: JW Lee , F Aminkeng , AP Bhavsar , K Shaw , BC Carleton

DOI: 10.1111/CGE.12392

关键词:

摘要: The vast range of genetic diversity contributes to a wonderful array human traits and characteristics. Unfortunately, consequence this is large variability in drug response between people, meaning that no single medication safe effective everyone. debilitating sometimes deadly consequences adverse reactions (ADRs) are major unmet problem modern medicine. Pharmacogenomics can uncover associations variation safety has the potential predict ADRs individual patients. Here we review pharmacogenomic successes leading changes clinical practice, as well areas probably be impacted by pharmacogenomics near future. We also discuss some challenges, solutions, remain for implementation testing into practice significant improvement safety.

参考文章(76)
Timothy J. Kropp, S. Leigh Verbois, Donna A. Volpe, Grainne A. McMahon Tobin, R. Daniel Mellon, Aspandiar G. Katki, Robert J. Parker, Thomas Colatsky, Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs Regulatory Toxicology and Pharmacology. ,vol. 59, pp. 385- 390 ,(2011) , 10.1016/J.YRTPH.2010.12.007
Y. Li, R.B. Womer, J.H. Silber, Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. European Journal of Cancer. ,vol. 40, pp. 2445- 2451 ,(2004) , 10.1016/J.EJCA.2003.08.009
J Sistonen, P Madadi, C J Ross, M Yazdanpanah, J W Lee, M L A Landsmeer, M Nauta, B C Carleton, G Koren, M R Hayden, Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clinical Pharmacology & Therapeutics. ,vol. 91, pp. 692- 699 ,(2012) , 10.1038/CLPT.2011.280
Ursula Amstutz, Colin JD Ross, Lucila I Castro‐Pastrana, Michael J Rieder, Neil H Shear, Michael R Hayden, Bruce C Carleton, CPNDS Consortium, None, HLA‐A*31:01 and HLA‐B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children Clinical Pharmacology & Therapeutics. ,vol. 94, pp. 142- 149 ,(2013) , 10.1038/CLPT.2013.55
R Skinner, ADJ Pearson, HA Amineddine, DB Mathias, AW Craft, Ototoxicity of cisplatinum in children and adolescents. British Journal of Cancer. ,vol. 61, pp. 927- 931 ,(1990) , 10.1038/BJC.1990.208
Catherine Ciszkowski, Parvaz Madadi, Michael S. Phillips, Albert E. Lauwers, Gideon Koren, Codeine, Ultrarapid-Metabolism Genotype, and Postoperative Death The New England Journal of Medicine. ,vol. 361, pp. 827- 828 ,(2009) , 10.1056/NEJMC0904266
Jörn Lötsch, Nils von Hentig, Rainer Freynhagen, Norbert Griessinger, Michael Zimmermann, Alexandra Doehring, Maren Rohrbacher, Reinhard Sittl, Gerd Geisslinger, Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and Genomics. ,vol. 19, pp. 429- 436 ,(2009) , 10.1097/FPC.0B013E32832B89DA
Mark J. Rieder, Alexander P. Reiner, Brian F. Gage, Deborah A. Nickerson, Charles S. Eby, Howard L. McLeod, David K. Blough, Kenneth E. Thummel, David L. Veenstra, Allan E. Rettie, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New England Journal of Medicine. ,vol. 352, pp. 2285- 2293 ,(2005) , 10.1056/NEJMOA044503
Dana Carroll, Precision genome engineering Current Biology. ,vol. 24, ,(2014) , 10.1016/J.CUB.2013.11.055
Javier G. Blanco, Wendy M. Leisenring, Vanessa M. Gonzalez-Covarrubias, Toana I. Kawashima, Stella M. Davies, Mary V. Relling, Leslie L. Robison, Charles A. Sklar, Marilyn Stovall, Smita Bhatia, Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline‐related congestive heart failure after childhood cancer Cancer. ,vol. 112, pp. 2789- 2795 ,(2008) , 10.1002/CNCR.23534